Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""decitabine"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 190
Tytuł:
Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML.
Autorzy:
Li H; Key Laboratory of Resource Biology and Biotechnology Western China, Ministry of Education; Provincial Key Laboratory of Biotechnology, College of Life Sciences, Northwest University, Xi'an, 710069, China.
Wang Y; Department of Hematology, Provincial People's Hospital, Xi'an, 710068, China.
Feng S; Key Laboratory of Resource Biology and Biotechnology Western China, Ministry of Education; Provincial Key Laboratory of Biotechnology, College of Life Sciences, Northwest University, Xi'an, 710069, China.
Chang K; Key Laboratory of Resource Biology and Biotechnology Western China, Ministry of Education; Provincial Key Laboratory of Biotechnology, College of Life Sciences, Northwest University, Xi'an, 710069, China.
Yu X; Key Laboratory of Resource Biology and Biotechnology Western China, Ministry of Education; Provincial Key Laboratory of Biotechnology, College of Life Sciences, Northwest University, Xi'an, 710069, China.
Yang F; Key Laboratory of Resource Biology and Biotechnology Western China, Ministry of Education; Provincial Key Laboratory of Biotechnology, College of Life Sciences, Northwest University, Xi'an, 710069, China.
Huang H; Key Laboratory of Resource Biology and Biotechnology Western China, Ministry of Education; Provincial Key Laboratory of Biotechnology, College of Life Sciences, Northwest University, Xi'an, 710069, China.
Wang Y; Key Laboratory of Resource Biology and Biotechnology Western China, Ministry of Education; Provincial Key Laboratory of Biotechnology, College of Life Sciences, Northwest University, Xi'an, 710069, China.
Li X; Institute of Hematology, School of Medicine, Northwest University, Xi'an, 710069, China. .; College of Life Science, Northwest University, 229 Taibai North Road, Xi'an, 710069, Shaanxi, China. .
Guan F; Key Laboratory of Resource Biology and Biotechnology Western China, Ministry of Education; Provincial Key Laboratory of Biotechnology, College of Life Sciences, Northwest University, Xi'an, 710069, China. .; College of Life Science, Northwest University, 229 Taibai North Road, Xi'an, 710069, Shaanxi, China. .
Pokaż więcej
Źródło:
Cell communication and signaling : CCS [Cell Commun Signal] 2023 Sep 22; Vol. 21 (1), pp. 255. Date of Electronic Publication: 2023 Sep 22.
Typ publikacji:
Video-Audio Media; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Oncogenes*
Myelodysplastic Syndromes*/drug therapy
Humans ; Decitabine/pharmacology ; N-Acetylglucosaminyltransferases ; Nuclear Proteins ; Twist-Related Protein 1
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy.
Autorzy:
Taib N; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Merhi M; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Inchakalody V; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Mestiri S; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Hydrose S; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Makni-Maalej K; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Raza A; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Sahir F; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Azizi F; Translational Research Institute, Academic Health System, Hamad Medical Corporation, 2030, Doha, Qatar.
Nizamuddin PB; Translational Research Institute, Academic Health System, Hamad Medical Corporation, 2030, Doha, Qatar.
Fernandes Q; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; College of Medicine, Qatar University, 2713, Doha, Qatar.
Yoosuf ZSKM; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; College of Health and Life Sciences, Hamad Bin Khalifa University, 34110, Doha, Qatar.
Almoghrabi S; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Al-Zaidan L; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Shablak A; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Uddin S; Translational Research Institute and Dermatology Institute, Academic Health System, Hamad Medical Corporation, 2030, Doha, Qatar.; Laboratory Animal Research Center, Qatar University, 2713, Doha, Qatar.
Maccalli C; Laboratory of Immune and Biological Therapy, Human Immunology Department, Research Branch, Sidra Medicine, 26999, Doha, Qatar.
Al Homsi MU; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Dermime S; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar. .; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar. .; College of Health and Life Sciences, Hamad Bin Khalifa University, 34110, Doha, Qatar. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2023 Mar 31; Vol. 21 (1), pp. 235. Date of Electronic Publication: 2023 Mar 31.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antigens, Neoplasm*/metabolism
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Male ; Humans ; Decitabine/pharmacology ; Decitabine/therapeutic use ; Membrane Proteins/genetics ; Membrane Proteins/metabolism ; Immunotherapy ; Cell Line, Tumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy.
Autorzy:
Liu Z; Central Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.; Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, 100101, China.; Shenzhen Key Laboratory of Synthetic Genomics, Guangdong Provincial Key Laboratory of Synthetic Genomics, CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, 518055, Shenzhen, China.; University of Chinese Academy of Sciences, 100049, Beijing, China.; Changping Laboratory, Yard 28, Science Park Road, Changping District, 102206, Beijing, China.
Li X; Changping Laboratory, Yard 28, Science Park Road, Changping District, 102206, Beijing, China.; Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Gao Y; Central Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.
Liu J; Changping Laboratory, Yard 28, Science Park Road, Changping District, 102206, Beijing, China.; Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Feng Y; Central Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.
Liu Y; Changping Laboratory, Yard 28, Science Park Road, Changping District, 102206, Beijing, China.; Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Wang J; Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, 100101, China.; University of Chinese Academy of Sciences, 100049, Beijing, China.
Wang C; Changping Laboratory, Yard 28, Science Park Road, Changping District, 102206, Beijing, China.; Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Wang D; Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310058, China. .; Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, 310058, China. .
He J; Central Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. .
Han W; Changping Laboratory, Yard 28, Science Park Road, Changping District, 102206, Beijing, China. .; Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China. .
Mei Q; Changping Laboratory, Yard 28, Science Park Road, Changping District, 102206, Beijing, China. .; Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China. .
Sun Y; Central Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. .; Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, 100101, China. .
Pokaż więcej
Źródło:
Molecular cancer [Mol Cancer] 2023 May 16; Vol. 22 (1), pp. 84. Date of Electronic Publication: 2023 May 16.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Epigenesis, Genetic*
CD8-Positive T-Lymphocytes*
Animals ; Mice ; Decitabine/pharmacology ; Immunotherapy ; Biomarkers/metabolism ; DNA Methylation ; Mice, Knockout ; Tumor Microenvironment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
5-aza-2'-deoxycitidine inhibits cell proliferation, extracellular matrix formation and Wnt/β-catenin pathway in human uterine leiomyomas.
Autorzy:
Carbajo-García MC; Fundación IVI, Instituto de Investigación Sanitaria La Fe, Avenida Fernando Abril Martorell 106, Torre A, Planta 1ª, 46026, Valencia, Spain.; Departamento de Pediatría, Obstetricia y Ginecología, Universidad de Valencia, Valencia, Spain.
Corachán A; Fundación IVI, Instituto de Investigación Sanitaria La Fe, Avenida Fernando Abril Martorell 106, Torre A, Planta 1ª, 46026, Valencia, Spain.; Departamento de Pediatría, Obstetricia y Ginecología, Universidad de Valencia, Valencia, Spain.
Segura-Benitez M; Fundación IVI, Instituto de Investigación Sanitaria La Fe, Avenida Fernando Abril Martorell 106, Torre A, Planta 1ª, 46026, Valencia, Spain.; Departamento de Pediatría, Obstetricia y Ginecología, Universidad de Valencia, Valencia, Spain.
Monleón J; Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Escrig J; Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Faus A; Fundación IVI, Instituto de Investigación Sanitaria La Fe, Avenida Fernando Abril Martorell 106, Torre A, Planta 1ª, 46026, Valencia, Spain.
Pellicer A; Fundación IVI, Instituto de Investigación Sanitaria La Fe, Avenida Fernando Abril Martorell 106, Torre A, Planta 1ª, 46026, Valencia, Spain.; IVIRMA Rome, Rome, Italy.
Cervelló I; Fundación IVI, Instituto de Investigación Sanitaria La Fe, Avenida Fernando Abril Martorell 106, Torre A, Planta 1ª, 46026, Valencia, Spain.
Ferrero H; Fundación IVI, Instituto de Investigación Sanitaria La Fe, Avenida Fernando Abril Martorell 106, Torre A, Planta 1ª, 46026, Valencia, Spain. .
Pokaż więcej
Źródło:
Reproductive biology and endocrinology : RB&E [Reprod Biol Endocrinol] 2021 Jul 08; Vol. 19 (1), pp. 106. Date of Electronic Publication: 2021 Jul 08.
Typ publikacji:
Journal Article
MeSH Terms:
Cell Proliferation/*drug effects
Decitabine/*pharmacology
Extracellular Matrix/*drug effects
Leiomyoma/*pathology
Uterine Neoplasms/*pathology
Wnt Signaling Pathway/*drug effects
Adult ; Antimetabolites, Antineoplastic/pharmacology ; Antimetabolites, Antineoplastic/therapeutic use ; Cell Proliferation/physiology ; Cell Survival/drug effects ; Cell Survival/physiology ; DNA Methylation/drug effects ; DNA Methylation/physiology ; Decitabine/therapeutic use ; Dose-Response Relationship, Drug ; Extracellular Matrix/metabolism ; Female ; Humans ; Leiomyoma/metabolism ; Middle Aged ; Prospective Studies ; Uterine Neoplasms/metabolism ; Wnt Signaling Pathway/physiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment.
Autorzy:
Patties I; Department of Radiooncology, University of Leipzig, Stephanstraße 9a, 04103, Leipzig, Germany. .
Kallendrusch S; Institute of Anatomy, University of Leipzig, Liebigstraße 13, 04103, Leipzig, Germany.
Böhme L; Department of Radiooncology, University of Leipzig, Stephanstraße 9a, 04103, Leipzig, Germany.
Kendzia E; Department of Radiooncology, University of Leipzig, Stephanstraße 9a, 04103, Leipzig, Germany.
Oppermann H; Department of Neurosurgery, University of Leipzig, Liebigstraße 20, 04103, Leipzig, Germany.
Gaunitz F; Department of Neurosurgery, University of Leipzig, Liebigstraße 20, 04103, Leipzig, Germany.
Kortmann RD; Department of Radiooncology, University of Leipzig, Stephanstraße 9a, 04103, Leipzig, Germany.
Glasow A; Department of Radiooncology, University of Leipzig, Stephanstraße 9a, 04103, Leipzig, Germany.
Pokaż więcej
Źródło:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2019 Oct 21; Vol. 38 (1), pp. 420. Date of Electronic Publication: 2019 Oct 21.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents, Alkylating/*therapeutic use
Cyclin-Dependent Kinase Inhibitor p21/*metabolism
Decitabine/*therapeutic use
Glioblastoma/*drug therapy
Glioblastoma/*radiotherapy
Radiotherapy/*methods
Temozolomide/*therapeutic use
Animals ; Antineoplastic Agents, Alkylating/pharmacology ; Cell Line, Tumor ; Decitabine/pharmacology ; Glioblastoma/pathology ; Humans ; Mice ; Temozolomide/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study.
Autorzy:
Li X; Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Ruijin No.2 Road, Shanghai, 200025, People's Republic of China.; Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Dong Y; Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Ruijin No.2 Road, Shanghai, 200025, People's Republic of China.; Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.; Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Li Y; Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Ruijin No.2 Road, Shanghai, 200025, People's Republic of China.; Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ren R; Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Ruijin No.2 Road, Shanghai, 200025, People's Republic of China.
Wu W; Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Ruijin No.2 Road, Shanghai, 200025, People's Republic of China.; Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhu H; Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Ruijin No.2 Road, Shanghai, 200025, People's Republic of China.; Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhang Y; Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Ruijin No.2 Road, Shanghai, 200025, People's Republic of China.; Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hu J; Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Ruijin No.2 Road, Shanghai, 200025, People's Republic of China. .; Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. .
Li J; Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Ruijin No.2 Road, Shanghai, 200025, People's Republic of China. .; Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2019 Aug 20; Vol. 19 (1), pp. 819. Date of Electronic Publication: 2019 Aug 20.
Typ publikacji:
Clinical Trial, Phase II; Journal Article
MeSH Terms:
Fetal Blood*
Antimetabolites, Antineoplastic/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Blood Transfusion/*methods
Consolidation Chemotherapy/*methods
Cytarabine/*therapeutic use
Decitabine/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Aged ; Antimetabolites, Antineoplastic/administration & dosage ; Cytarabine/administration & dosage ; Decitabine/administration & dosage ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Prospective Studies ; Survival Rate
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
Autorzy:
Moyo TK; Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, Nashville, TN, 777 PRB, USA.; Levine Cancer Institute, Charlotte, NC, USA.
Mendler JH; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Itzykson R; Paris Diderot University, Paris, France.
Kishtagari A; Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, Nashville, TN, 777 PRB, USA.
Solary E; Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Seegmiller AC; Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, Nashville, TN, 777 PRB, USA.
Gerds AT; Cleveland Clinic, Cleveland, OH, USA.
Ayers GD; Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, Nashville, TN, 777 PRB, USA.
Dezern AE; Johns Hopkins University, Baltimore, MD, USA.
Nazha A; Cleveland Clinic, Cleveland, OH, USA.
Valent P; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
van de Loosdrecht AA; VU University Medical Center, Amsterdam, Netherlands.
Onida F; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Pleyer L; Third Medical Department With Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria.; Salzburg Cancer Research Institute Center for Clinical Cancer and Immunology Trials, Salzburg, Austria.
Cirici BX; Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Bellaterr, Spain.
Tibes R; Mayo Clinic, Scottsdale, AZ, USA.
Geissler K; Sigmund Freud University, Vienna, Austria.
Komrokji RS; H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Zhang J; University of Wisconsin-Madison, Madison, WI, USA.
Germing U; Department of Hematology, Oncology, and Clinical Immunology, University of Duesseldorf, Duesseldorf, Germany.
Steensma DP; Dana-Farber Cancer Institute, Boston, MA, USA.
Wiseman DH; University of Manchester, Manchester, UK.
Pfeilstöecker M; Hanusch Hospital and Ludwig Boltzmann Institute for Hematology and Oncology, Vienna, Austria.
Elena C; University of Pavia, Pavia, Italy.
Cross NCP; School of Medicine, University of Southampton, Southampton, UK.
Kiladjian JJ; Université de Paris, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM CIC 1427, Paris, France.
Luebbert M; University of Freiburg, Freiburg, Germany.
Mesa RA; Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA.
Montalban-Bravo G; MD Anderson Cancer Center, Houston, TX, USA.
Sanz GF; Hospital Universitario Y Politécnico La Fe, Valencia, Spain.
Platzbecker U; University Hospital Leipzig, Leipzig, Germany.
Patnaik MM; Mayo Clinic, Rochester, MN, USA.
Padron E; H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Santini V; MDS UNIT, University of Florence, HematologyFlorence, Italy.
Fenaux P; Paris Diderot University, Paris, France.
Savona MR; Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, Nashville, TN, 777 PRB, USA. .
Pokaż więcej
Corporate Authors:
MDS/MPN International Working Group
Źródło:
BMC cancer [BMC Cancer] 2022 Sep 24; Vol. 22 (1), pp. 1013. Date of Electronic Publication: 2022 Sep 24.
Typ publikacji:
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
MeSH Terms:
Myelodysplastic-Myeloproliferative Diseases*
Quality of Life*
Acetonitriles ; Cytidine Deaminase ; DNA/therapeutic use ; Decitabine/therapeutic use ; Humans ; Methyltransferases ; Prospective Studies ; Pyrazoles ; Pyrimidines ; Pyrroles ; Syndrome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.
Autorzy:
Huang J; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing, 210029, China.
Zhao H; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing, 210029, China.; Department of Oncology, The Second Affiliated Hospital of Southeast University, Zhongfu Road 1-1, Nanjing, 210003, China.
Hong M; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing, 210029, China.
Zhu H; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing, 210029, China.
Zhu Y; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing, 210029, China.
Lian Y; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing, 210029, China.
Li S; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing, 210029, China.
Li J; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing, 210029, China.
Qian S; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing, 210029, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2018 Dec 19; Vol. 18 (1), pp. 1269. Date of Electronic Publication: 2018 Dec 19.
Typ publikacji:
Clinical Trial; Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Blood Platelets/*drug effects
Decitabine/*administration & dosage
Leukemia, Myeloid, Acute/*drug therapy
Aclarubicin/administration & dosage ; Aclarubicin/adverse effects ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; China ; Cytarabine/administration & dosage ; Cytarabine/adverse effects ; Decitabine/adverse effects ; Disease-Free Survival ; Female ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Granulocyte Colony-Stimulating Factor/adverse effects ; Humans ; Induction Chemotherapy/adverse effects ; Leukemia, Myeloid, Acute/blood ; Leukemia, Myeloid, Acute/pathology ; Male ; Middle Aged ; Platelet Count ; Prognosis ; Remission Induction
SCR Protocol:
CAG protocol
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome.
Autorzy:
Almasri J; Evidence-Based Practice Research Program, Mayo Clinic, Rochester, MN, USA.; Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, USA.
Alkhateeb HB; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Firwana B; Division of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Sonbol MB; Division of Hematology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA.
Damlaj M; Division of Hematology & HSCT, Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Wang Z; Evidence-Based Practice Research Program, Mayo Clinic, Rochester, MN, USA.; Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, USA.
Murad MH; Evidence-Based Practice Research Program, Mayo Clinic, Rochester, MN, USA. .; Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, USA. .
Al-Kali A; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Pokaż więcej
Źródło:
Systematic reviews [Syst Rev] 2018 Sep 19; Vol. 7 (1), pp. 144. Date of Electronic Publication: 2018 Sep 19.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Azacitidine*/analogs & derivatives
Azacitidine*/therapeutic use
Decitabine*/therapeutic use
Myelodysplastic Syndromes*/drug therapy
Network Meta-Analysis*
Humans ; Blood Transfusion ; Mortality ; Quality of Life
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Aberrant expression of GSTM5 in lung adenocarcinoma is associated with DNA hypermethylation and poor prognosis.
Autorzy:
Hao X; Department of Biochemistry, Inspection Institute, Harbin Medical University-Daqing, Daqing, China.
Zhang J; School of Biomedical Sciences and Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Hong Kong, China.
Chen G; Department of Biopharmaceutical Sciences, College of Pharmacy, Harbin Medical University-Daqing, No. 39 Xinyang Street, High-tech Zone, Daqing, 163319, Heilongjiang Province, China.
Cao W; Department of Biopharmaceutical Sciences, College of Pharmacy, Harbin Medical University-Daqing, No. 39 Xinyang Street, High-tech Zone, Daqing, 163319, Heilongjiang Province, China.
Chen H; Department of Biopharmaceutical Sciences, College of Pharmacy, Harbin Medical University-Daqing, No. 39 Xinyang Street, High-tech Zone, Daqing, 163319, Heilongjiang Province, China.
Chen S; Department of Biopharmaceutical Sciences, College of Pharmacy, Harbin Medical University-Daqing, No. 39 Xinyang Street, High-tech Zone, Daqing, 163319, Heilongjiang Province, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 Jun 21; Vol. 22 (1), pp. 685. Date of Electronic Publication: 2022 Jun 21.
Typ publikacji:
Journal Article
MeSH Terms:
Adenocarcinoma of Lung*/pathology
Lung Neoplasms*/pathology
Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; DNA/metabolism ; DNA Methylation ; Decitabine ; Gene Expression Regulation, Neoplastic ; Glutathione/metabolism ; Glutathione Transferase ; Humans ; Prognosis ; Transferases/genetics ; Transferases/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements.
Autorzy:
Roolf C; Department of Medicine, Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Ernst-Heydemann-Str. 6, 18057, Rostock, Germany.
Richter A; Department of Medicine, Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Ernst-Heydemann-Str. 6, 18057, Rostock, Germany.
Konkolefski C; Department of Medicine, Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Ernst-Heydemann-Str. 6, 18057, Rostock, Germany.
Knuebel G; Department of Medicine, Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Ernst-Heydemann-Str. 6, 18057, Rostock, Germany.
Sekora A; Department of Medicine, Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Ernst-Heydemann-Str. 6, 18057, Rostock, Germany.
Krohn S; Department of Medicine, Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Ernst-Heydemann-Str. 6, 18057, Rostock, Germany.
Stenzel J; Department of Nuclear Medicine, Rostock University Medical Center, University of Rostock, Gertrudenplatz 1, 18057, Rostock, Germany.
Krause BJ; Department of Nuclear Medicine, Rostock University Medical Center, University of Rostock, Gertrudenplatz 1, 18057, Rostock, Germany.
Vollmar B; Institute of Experimental Surgery, Rostock University Medical Center, University of Rostock, Schillingallee 69a, 18057, Rostock, Germany.
Murua Escobar H; Department of Medicine, Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Ernst-Heydemann-Str. 6, 18057, Rostock, Germany.
Junghanss C; Department of Medicine, Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Ernst-Heydemann-Str. 6, 18057, Rostock, Germany. .
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2018 May 04; Vol. 11 (1), pp. 62. Date of Electronic Publication: 2018 May 04.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antimetabolites, Antineoplastic/*therapeutic use
Decitabine/*therapeutic use
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy
Animals ; Antimetabolites, Antineoplastic/pharmacology ; Cell Line, Tumor ; Decitabine/pharmacology ; Disease Models, Animal ; Gene Rearrangement ; Humans ; Mice
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Low-dose hypomethylating agents cooperate with ferroptosis inducers to enhance ferroptosis by regulating the DNA methylation-mediated MAGEA6-AMPK-SLC7A11-GPX4 signaling pathway in acute myeloid leukemia.
Autorzy:
Feng, Shuya (AUTHOR)
Yuan, Yigang (AUTHOR)
Lin, Zihan (AUTHOR)
Li, Min (AUTHOR)
Ye, Daijiao (AUTHOR)
Shi, Liuzhi (AUTHOR)
Li, Danyang (AUTHOR)
Zhao, Min (AUTHOR)
Meng, Chen (AUTHOR)
He, Xiaofei (AUTHOR)
Wu, Shanshan (AUTHOR)
Xiong, Fang (AUTHOR)
Ye, Siyu (AUTHOR)
Yang, Junjun (AUTHOR)
Zhuang, Haifeng (AUTHOR)
Hong, Lili (AUTHOR)
Gao, Shenmeng (AUTHOR)
Pokaż więcej
Źródło:
Experimental Hematology & Oncology. 2/20/2024, Vol. 13, p1-20. 20p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics.
Autorzy:
Javorniczky, Nora Rebeka (AUTHOR)
Grishina, Olga (AUTHOR)
Hund, Inga (AUTHOR)
Pantic, Milena (AUTHOR)
Pfeifer, Dietmar (AUTHOR)
Schmoor, Claudia (AUTHOR)
Thomas, Johanna (AUTHOR)
Duyster, Justus (AUTHOR)
Becker, Heiko (AUTHOR)
Lübbert, Michael (AUTHOR)
Pokaż więcej
Źródło:
Clinical Epigenetics. 11/28/2023, Vol. 15 Issue 1, p1-5. 5p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.
Autorzy:
Berg, Johannes Lorenz (AUTHOR)
Perfler, Bianca (AUTHOR)
Hatzl, Stefan (AUTHOR)
Mayer, Marie-Christina (AUTHOR)
Wurm, Sonja (AUTHOR)
Uhl, Barbara (AUTHOR)
Reinisch, Andreas (AUTHOR)
Klymiuk, Ingeborg (AUTHOR)
Tierling, Sascha (AUTHOR)
Pregartner, Gudrun (AUTHOR)
Bachmaier, Gerhard (AUTHOR)
Berghold, Andrea (AUTHOR)
Geissler, Klaus (AUTHOR)
Pichler, Martin (AUTHOR)
Hoefler, Gerald (AUTHOR)
Strobl, Herbert (AUTHOR)
Wölfler, Albert (AUTHOR)
Sill, Heinz (AUTHOR)
Zebisch, Armin (AUTHOR)
Pokaż więcej
Źródło:
Clinical Epigenetics. 1/6/2021, Vol. 13 Issue 1, p1-10. 10p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients
Autorzy:
Ma, YunjuAff1, Aff2
Dai, HaipingAff1, Aff2
Cui, QingyaAff1, Aff2
Liu, SiningAff1, Aff2
Kang, Liqing
Lian, XiayingAff1, Aff2
Cui, WeiAff1, Aff2
Yin, JiaAff1, Aff2
Liu, LinglingAff1, Aff2
Cai, MengjieAff1, Aff2
Yu, Lei
Wu, DepeiAff1, Aff2, IDs4016402300397z_cor12
Tang, XiaowenAff1, Aff2, IDs4016402300397z_cor13
Pokaż więcej
Źródło:
Experimental Hematology & Oncology. 12(1)
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Immune responses to azacytidine in animal models of inflammatory disorders: a systematic review.
Autorzy:
Landman S; Department of Laboratory Medicine-Laboratory Medical Immunology, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, The Netherlands.
van der Horst C; Department of Laboratory Medicine-Laboratory Medical Immunology, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, The Netherlands.
van Erp PEJ; Department of Dermatology, Radboudumc, Nijmegen, The Netherlands.
Joosten I; Department of Laboratory Medicine-Laboratory Medical Immunology, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, The Netherlands.
de Vries R; Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE), Department for Health Evidence, Radboud Institute for Health Sciences, Radboudumc, Nijmegen, The Netherlands.
Koenen HJPM; Department of Laboratory Medicine-Laboratory Medical Immunology, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, The Netherlands. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2021 Jan 06; Vol. 19 (1), pp. 11. Date of Electronic Publication: 2021 Jan 06.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms:
Azacitidine*/pharmacology
Azacitidine*/therapeutic use
T-Lymphocytes, Regulatory*
Animals ; Decitabine ; Immunity ; Models, Animal
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 190

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies